{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06409390",
            "orgStudyIdInfo": {
                "id": "MCC-22617"
            },
            "organization": {
                "fullName": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            },
            "briefTitle": "Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer",
            "officialTitle": "A Pilot Study of Sequential (\"First Strike, Second Strike\") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "sequential-therapies-modeled-on-evolutionary-dynamics-for-breast-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-04-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-07",
            "studyFirstSubmitQcDate": "2024-05-07",
            "studyFirstPostDateStruct": {
                "date": "2024-05-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "H. Lee Moffitt Cancer Center and Research Institute",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Breast Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 15,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Sequential therapy",
                    "type": "EXPERIMENTAL",
                    "description": "In this study sequential therapies will be administered.\n\nStrike 1: Cytoxan/Taxotere/GM-CSF Strike 2: Sacituzumab govitecan or trastuzumab deruxtecan Strike 3: Capecitabine Strike 4: Fulvestrant + CDK 4/6 inhibitor (ribociclib or abemaciclib)",
                    "interventionNames": [
                        "Drug: Taxotere",
                        "Drug: Cytoxan",
                        "Drug: Trastuzumab deruxtecan",
                        "Drug: Sacituzumab govitecan",
                        "Drug: Xeloda",
                        "Drug: Fulvestrant",
                        "Drug: Ribociclib",
                        "Drug: Abemaciclib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Taxotere",
                    "description": "75 mg/m2 once every 21 days for 4 cycles",
                    "armGroupLabels": [
                        "Sequential therapy"
                    ],
                    "otherNames": [
                        "Docetaxel"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cytoxan",
                    "description": "600 mg/m2 once every 21 days for 4 cycles",
                    "armGroupLabels": [
                        "Sequential therapy"
                    ],
                    "otherNames": [
                        "Cyclophosphamide"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Trastuzumab deruxtecan",
                    "description": "5.4 mg/kg once every 21 days for 5 cycles",
                    "armGroupLabels": [
                        "Sequential therapy"
                    ],
                    "otherNames": [
                        "Enhertu"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Sacituzumab govitecan",
                    "description": "10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles",
                    "armGroupLabels": [
                        "Sequential therapy"
                    ],
                    "otherNames": [
                        "Trodelvy"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Xeloda",
                    "description": "1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles",
                    "armGroupLabels": [
                        "Sequential therapy"
                    ],
                    "otherNames": [
                        "Capecitabine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fulvestrant",
                    "description": "500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles",
                    "armGroupLabels": [
                        "Sequential therapy"
                    ],
                    "otherNames": [
                        "Faslodex"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ribociclib",
                    "description": "600 mg orally daily 21 days on, 7 days off",
                    "armGroupLabels": [
                        "Sequential therapy"
                    ],
                    "otherNames": [
                        "Kisqali"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Abemaciclib",
                    "description": "150 mg by mouth twice daily",
                    "armGroupLabels": [
                        "Sequential therapy"
                    ],
                    "otherNames": [
                        "Verzenio"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Feasibility of Sequential Therapy",
                    "description": "The proportion of patients able to complete the sequence of therapies by the conclusion of the trial.",
                    "timeFrame": "Up to 18 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Safety and Tolerability",
                    "description": "The proportion of patients who experience adverse events or serious adverse events.",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "No Evidence of Disease (NED)",
                    "description": "The proportion of patients who are able to reach NED status by the conclusion of the trial will be calculated.",
                    "timeFrame": "Up to 18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients 18 years or older\n* Histologically or cytologically confirmed diagnosis of hormone positive HER2 negative metastatic breast cancer per ASCO/CAP criteria (Allison et al, 2020, Wolff et al, 2018), with diagnosis established through either a breast/axillary biopsy or biopsy of a metastatic lesion.\n* Hormone positive MBC previously treated with endocrine therapy with either an aromatase inhibitor or Tamoxifen (alone or in combination with a CDK4/6 inhibitor).\n* Elevated breast tumor markers which may include cancer antigen 15-3 (CA 15-3) levels above the institutional upper limit of normal (ULN) range of 0.0-31.0 U/mL, cancer antigen 27-29 (CA 27-29) (range \\<38 U/mL) and/or elevated Carcinoembryonic antigen (CEA) above institutional upper limit of normal (range 0.0 - 5.2 ng/mL).\n* Presence of measurable disease on imaging via RECIST v1.1.\n* ECOG performance status 0-1.\n* Participants must have adequate organ and marrow function as defined in the protocol.\n* A negative pregnancy test for pre-menopausal women of childbearing potential.\n* Pre-menopausal women of childbearing potential who are sexually active with a male partner must agree to use adequate contraception prior to the study, for the duration of study participation.\n* Inclusion of minorities: patients of all races and ethnic groups who meet the above inclusion and below exclusion criteria are eligible for this trial.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Ability to understand and the willingness to sign a written informed consent document or have a legally authorized representative sign on the participant's behalf.\n\nExclusion Criteria:\n\n* Have previously received Fulvestrant for treatment of their breast cancer.\n* History of allergic reactions attributed to the study drugs.\n* Documented brain metastasis or active or newly diagnosed CNS metastases, including meningeal carcinomatosis, because systemic treatment would need to be paused for these patients.\n* Treatment with any investigational compound within 30 days prior to the first dose of study drugs or during this study.\n* Diagnosis or treatment for another systemic malignancy within 2 years before the first dose of study drugs, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.\n* Uncontrolled intercurrent illness including-but not limited to-ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Patients with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis.\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.\n* Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen \\[HBsAg\\]), or hepatitis C (HCV). Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Participants with positive HCV antibody are eligible if polymerase chain reaction is negative for HCV RNA.\n* Concurrent or prior use of immunosuppressive medication within 14 days before the first dose of study drugs, with the following exceptions: premedication with dexamethasone, intranasal, inhaled, topical or local steroid injections, systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent; steroids as premedication for hypersensitivity reactions (e.g., premedication for iodinated contrast allergy before CT scan).\n* Inability to comply with protocol requirements.\n* Pregnant and/or breastfeeding women are excluded.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jennifer Childress",
                    "role": "CONTACT",
                    "phone": "813-745-0578",
                    "email": "jennifer.childress@moffitt.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Aixa Soyano, MD",
                    "affiliation": "Moffitt Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Childress",
                            "role": "CONTACT",
                            "phone": "813-745-0578"
                        },
                        {
                            "name": "Aixa Soyano, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Dana Ataya, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000077143",
                    "term": "Docetaxel"
                },
                {
                    "id": "D000069287",
                    "term": "Capecitabine"
                },
                {
                    "id": "D000068878",
                    "term": "Trastuzumab"
                },
                {
                    "id": "D000077267",
                    "term": "Fulvestrant"
                },
                {
                    "id": "C000608132",
                    "term": "Sacituzumab govitecan"
                },
                {
                    "id": "C000614160",
                    "term": "Trastuzumab deruxtecan"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000065171",
                    "term": "Estrogen Receptor Antagonists"
                },
                {
                    "id": "D000004965",
                    "term": "Estrogen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018796",
                    "term": "Immunoconjugates"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M287620",
                    "name": "Sacituzumab govitecan",
                    "asFound": "Anorexia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M377",
                    "name": "Capecitabine",
                    "asFound": "200",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1723",
                    "name": "Fulvestrant",
                    "asFound": "Challenge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1668",
                    "name": "Docetaxel",
                    "asFound": "Blood pressure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M325",
                    "name": "Trastuzumab",
                    "asFound": "Follow-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M233243",
                    "name": "Trastuzumab deruxtecan",
                    "asFound": "Tilt",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M8114",
                    "name": "Estrogen Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30483",
                    "name": "Estrogen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20855",
                    "name": "Immunoconjugates",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}